First-phase insulin secretion: can its evaluation direct therapeutic approaches?
- PMID: 36858875
- DOI: 10.1016/j.tem.2023.02.001
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Abstract
Our work is aimed at unraveling the role of the first-phase insulin secretion in the natural history of type 2 diabetes mellitus (T2DM) and its interrelationship with insulin resistance and with β cell function and mass. Starting from pathophysiology, we investigate the impact of impaired secretion on glucose homeostasis and explore postmeal hyperglycemia as the main clinical feature, underlining its relevance in the management of the disease. We also review dietary and pharmacological approaches aimed at improving early secretory defects and restoring residual β cell function. Furthermore, we discuss possible approaches to detect early secretory defects in clinical practice. By providing a journey through human and animal data, we attempt a unification of the recent evidence in an effort to offer a new outlook on β cell secretion.
Keywords: first phase, β cell function; insulin secretion; postmeal hyperglycemia; type 2 diabetes.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no conflicts of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical